The present invention relates to methods and pharmaceutical compositions for reducing arterial stiffness in a human patient showing at least one symptom selected from increased pulse wave velocity (PWV) and increased pulse pressure (PP) comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof in a 1:1 molar ratio.